Based on the observed influence of FcγRIIIa polymorphisms in vitro, several retrospective studies in patients with non-hodgkin lymphomas (NHL) treated with rituximab have looked for a possible correlation between FcγRIIIa polymorphisms and clinical outcomes (11–14). This evidence concerns the gene FCGR3A and non-Hodgkin lymphoma.